UBC Opens New Office in Tokyo
United BioSource Corporation (UBC; Bethesda, MD) announced the opening of its newest global office in Tokyo, Japan. The office will be led by Kumpei Kobayashi, PharmD, a biopharmaceutical industry veteran with over 20 years of product development experience throughout the Asia-Pacific region. Personnel in the new UBC office will support the company’s investigator training and certification solutions as well as ongoing clinical research monitoring services in the region.
“The UBC office in Tokyo will help us support our clients’ research projects with local personnel who understand the needs of patients, health care professionals and regulators in this important region. Local knowledge of the Asia-Pacific markets is absolutely essential when we help clients manage research projects that are often very large, complex and supported by significant financial investments,” said Catherine Spear, UBC’s Senior Vice President.
Dr. Kobayashi will be joined by several members of UBC’s management team, including David Miller, MD, who has served as a scientific leader on several Pan-Asian and multi-national studies involving sites in Japan, Taiwan, Korea, China, Hong Kong, India, Philippines, Singapore, and Thailand.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
